Skip to search formSkip to main contentSkip to account menu

Ranirestat

Known as: (3R)-2'-(4-Bromo-2-fluorobenzyl)spiro(pyrrolidine-3,4'(1'H)-pyrrolo(1,2-a)pyrazine)-1',2,3',5(2'H)-tetrone 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Ranirestat is an aldose reductase inhibitor hypothesized to improve diabetic neuropathy. An open‐label, single‐dose, parallel… 
2019
2019
Distal sensory-motor polyneuropathy is one of the most frequent diabetic complications. However, few therapies address the… 
Review
2011
Review
2011
Clinicaltrials.gov is the registry of clinical trials that is run by the US National Library of Medicine for the NIH. Originally… 
2009
2009
Using ranirestat, an aldose reductase (AR) inhibitor, we investigated the relationship between sorbitol and fructose levels in… 
Review
2009
Review
2009
This review summarizes recent advances in the development of efficient routes based on enantioselective catalysis for the… 
Review
2008
Review
2008
Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of ranirestat, an oral aldose reductase… 
2006
2006
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2004
2004
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…